ArticleEuropean journal of nuclear medicine and molecular imaging2020
The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia.
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Enhancing reader confidence through dual-time imaging and alternative reconstruction algorithms with [EJNMMI research · 2026Article
- PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.Targeted oncology · 2025Review
- The impact of long axial field of view (LAFOV) PET on oncologic imaging.European journal of radiology · 2025Review
- First-in-human study of PSMA-targeting agent, [European journal of nuclear medicine and molecular imaging · 2024Article
- The clinical acceptability of short versus long duration acquisitions for head and neck cancer using long-axial field-of-view PET/CT: a retrospective evaluation.European journal of nuclear medicine and molecular imaging · 2024Article
- Comparison of early and lateScientific reports · 2023Article
- Intra-Individual Comparison of Physiologic [Cancers · 2023Article
- Multi-timepoint imaging with PSMA-targeted [Annals of nuclear medicine · 2023Article
- Long-axial field-of-view PET/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Review
- Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.European journal of nuclear medicine and molecular imaging · 2023Article
- Assessment of malignancy and PSMA expression of uncertain bone foci in [European journal of nuclear medicine and molecular imaging · 2022Article
- Abbreviated scan protocols to captureEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent-Impact of Delayed Imaging.Journal of clinical medicine · 2022Article
- Diagnostic accuracy of [European journal of nuclear medicine and molecular imaging · 2022Article
- Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-bodyEJNMMI research · 2022Article
- Positron emission tomography and computed tomography with [European journal of nuclear medicine and molecular imaging · 2022Article
- Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.Annals of nuclear medicine · 2022Article
- Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences.European journal of nuclear medicine and molecular imaging · 2021Article
- The influence of digital PET/CT on diagnostic certainty and interrater reliability in [European radiology · 2021Article
- Intra-patient comparison of physiologicCancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDifferentiating between prostate cancer (PC) lesions and benign structures which exhibit radiotracer uptake in PSMA-ligand PET/CT can be challenging. Additional late imaging has been shown to be a powerful method for the discrimination between PC and non-PC lesions, owing to the increasing tracer uptake of the former. Nevertheless, there are no pre-existing studies which describe the dynamic tracer uptake for ganglia, which this present study aims to address.
methodsFifty consecutive patients with PC who received standard and late
resultsOverall, 86 PSMA-positive ganglia were identified in 70% (n = 35) of the patients. Five ganglia exhibited PSMA avidity at late imaging only, and three at standard imaging only. A total of 66 lesions suggestive for PC were detected in 44 patients (88%), of which 45% (n = 30) were morphologically identified as lymph nodes (LN), the remainder being locally recurrent lesions or bone metastases. No solid organ metastases were present in our cohort. At late scanning, 73% of the LN exhibited an increase in SUVmax, whereas 65% of the ganglia exhibited a decreasing or stable SUVmax.
conclusionWhereas the presence of increasing tracer uptake in potential PC lesions can provide additional data about the likelihood of malignancy, increasing SUVmax alone does not reliably differentiate between ganglia and PC lesions and is a potential diagnostic pitfall. We therefore recommend high-resolution CT to enable morphological characterisation of ganglia.
Indexed as
Identifiers
31865408What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.